Effect of Addition and Subtraction Therapy of Xiaoyaosan Combined with Simotang to Gut-brain Axis of Patients with Irritable Bowel Syndrome with Predominant Constipation and Syndrome of Stagnation of Liver Qi
Clinic|更新时间:2020-12-10
|
Effect of Addition and Subtraction Therapy of Xiaoyaosan Combined with Simotang to Gut-brain Axis of Patients with Irritable Bowel Syndrome with Predominant Constipation and Syndrome of Stagnation of Liver Qi
Chinese Journal of Experimental Traditional Medical FormulaeVol. 26, Issue 22, Pages: 53-58(2020)
ZHEN He-ping,ZHANG Zhi-bin,WEI Xian-peng,et al.Effect of Addition and Subtraction Therapy of Xiaoyaosan Combined with Simotang to Gut-brain Axis of Patients with Irritable Bowel Syndrome with Predominant Constipation and Syndrome of Stagnation of Liver Qi[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(22):53-58.
ZHEN He-ping,ZHANG Zhi-bin,WEI Xian-peng,et al.Effect of Addition and Subtraction Therapy of Xiaoyaosan Combined with Simotang to Gut-brain Axis of Patients with Irritable Bowel Syndrome with Predominant Constipation and Syndrome of Stagnation of Liver Qi[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(22):53-58. DOI: 10.13422/j.cnki.syfjx.20200831.
Effect of Addition and Subtraction Therapy of Xiaoyaosan Combined with Simotang to Gut-brain Axis of Patients with Irritable Bowel Syndrome with Predominant Constipation and Syndrome of Stagnation of Liver Qi
To observe clinical effect of addition and subtraction therapy of Xiaoyaosan combined with Simotang to irritable bowel syndrome with predominant constipation (IBS-C) and syndrome of stagnation of liver Qi and to study influence to gut-brain axis.
Method
2
One hundred and forty-four patients were randomly divided into control group (72 cases) and observation group (72 cases) by random number table. The 66 patients in control group completed the therapy (2 patients were falling off or missing visit, 5 patients were eliminate), 65 patients in observation group completed the therapy (4 patients were falling off or missing visit, 2 patients were eliminate). Patients in control group got Simotang, 20 mL/time, 3 times/day. In control group, patients in observation group added addition and subtraction therapy of Xiaoyaosan combined with Simotang, 1 dose/day. And courses of treatment in two groups were 4 weeks. Before and after treatment, degree of abdominal pain, irritable bowel syndrome (IBS) symptom severity scale (IBS-SSS), quality of life in irritable bowel syndrome (IBS-QOL), syndrome of stagnation of liver Qi, scores of Hamilton anxiety scale-14(HAMA-14), Hamilton depression scale-17(HAMD-17), complete spontaneous bowel movement (CSBM), response rate of abdominal pain and defecation, remission rate of IBS-SSS were all recorded. And levels of vasoactive intestinal peptide (VIP), substance P (SP), neuropeptide Y (NPY), 5-hydroxytryptamine (5-HT), somatostatin (SS) and calcitonin related gene peptide were detected, and safety was evaluated.
Result
2
Degree of abdominal pain, scores of IBS-SSS, syndrome of stagnation of liver Qi , HAMA-14, HAMD-17 and levels of VIP, NPY, 5-HT, SS and CGRP in observation group were all lower than those in control group (
P
<
0.01). And times of CSBM, score of IBS-QOL and level of SP were all higher than those in control group (
P
<
0.01). Besides, response rate of abdominal pain and defecation and remission rate of IBS-SSS in observation group 95.38%(62/65), 93.85%(61/65) and 90.77%(59/65)were higher than 83.33%(55/66),78.79%(52/66)and 75.76%(50/66) in control group (
P
<
0.05). And curative effect of traditional Chinese medicine (TCM) syndromes in was better than that in control group (
Z
=2.1034,
P
<
0.05). No serious adverse events happened and no adverse reaction caused by TCM.
Conclusion
2
Addition and subtraction therapy of Xiaoyaosan combined with Simotang can significantly ameliorate IBS-C symptoms, reduce bad mood, improve patients' quality of life, regulate a variety of brain gut peptide factors, and improve brain gut axis disorder. It has good clinical efficacy and safety.
SLATTERY S A , NIAZ O , AZIZ Q , et al . Systematic review with Meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea [J]. Aliment Pharmacol Ther , 2015 , 42 ( 1 ): 3 - 11 .
FORD A C , LACY B E , TALLEY N J . Irritable bowel syndrome [J]. N Engl J Med , 2017 , 3376 ( 26 ): 2566 - 2578 .
AIZAWA E , SATO Y , KOCHIYAMA T , et al . Altered cognitive function of prefrontal cortex during error feedback in patients with irritable bowel syndrome, based on fMRI and dynamic causal modeling [J]. Gastroenterology , 2012 , 143 ( 5 ): 1188 - 1198 .
ZHENG Y , YU T , TANG Y , et al . Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials [J]. PLoS One , 2017 , 12 ( 3 ): e0172846 .
TAP J , DERRIEN M , TORNBLOM H , et al . Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome [J]. Gastroenterology , 2017 , 152 ( 1 ): 111 - 123 .
EL-SALHY M , GILJA O H . Abnormalities in ileal stem, neurogenin 3, and enteroendocrine cells in patients with irritable bowel syndrome [J]. BMC Gastroenterol , 2017 , 17 ( 1 ): 90 - 95 .
Herbal Cake-separated Moxibustion Improves Cognitive Function in Rat Model of Chronic Fatigue Syndrome via PI3K/Beclin1 Signaling Pathway
Clinical and Mechanism of Modified Xiaoyaosan and Its Effective Components in Treatment of Thyroid Diseases: A Review
Mechanism of Herbal Cake-separated Moxibustion in Improving Neuroimmune Inflammation in Rats with Chronic Fatigue Syndrome by Interfering TLR4/MyD88/NF-κB Pathway
Xiaoyaosan Regulates HPT Axis in Rat Model with Syndrome of Liver Depression and Spleen Deficiency via CGA/GPX2/TSHβ Pathway for Thyroid Hormone Synthesis
Regulatory Effect of Xiaoyaosan Combined with Pirfenidone on Idiopathic Pulmonary Fibrosis and Depression in Rats Based on p38 MAPK/NF-κB Inflammatory Pathway
Related Author
ZHAI Chuntao
HOU Yawei
SHI Linjuan
WANG Yixiao
TIAN Yuefeng
LI Shanshan
FU Yu
WEI Dandan
Related Institution
Second Clinical College of Shanxi University of Chinese Medicine
First Affiliated Hospital of Henan University of Chinese Medicine
The First Clinical Medical College of Henan University of Chinese Medicine
Guangxi Key Laboratory of Chinese Medicine Foundation Research, Guangxi University of Chinese Medicine